Nifty Pharma Stocks List
10 stocks · Updated daily from NSE
Pharma can look defensive on the surface and brutally demanding underneath
Pharma often attracts investors looking for defensiveness, but the reality is more layered. Regulatory scrutiny, product mix, US exposure, domestic franchise strength, API economics, and margin sustainability all influence how pharma stocks behave. A good pharma page helps investors separate comfort-seeking from real analysis.
What to watch on this page
Study how the market is rewarding different types of pharma businesses: domestic formulations, export-heavy generics, hospitals, specialty plays, or integrated manufacturers. Compliance quality and product depth often matter as much as headline growth.
| # | Company | Symbol | Price | Change | Mkt Cap | P/E | Score |
|---|---|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited Pharmaceuticals | SUNPHARMA | ₹1773.40 | +0.20% | ₹425K Cr | 35.2x | 72 |
| 2 | Divi's Laboratories Limited Pharmaceuticals | DIVISLAB | ₹10037.50 | -0.26% | ₹266K Cr | 91.1x | |
| 3 | Torrent Pharmaceuticals Limited Pharmaceuticals | TORNTPHARM | ₹4738.50 | +1.90% | ₹160K Cr | 75.7x | |
| 4 | Apollo Hospitals Enterprise Limited Hospital | APOLLOHOSP | ₹8599.50 | +1.89% | ₹124K Cr | 59.2x | |
| 5 | Zydus Lifesciences Limited Pharmaceuticals | ZYDUSLIFE | ₹1188.10 | -4.23% | ₹119K Cr | 26.5x | |
| 6 | Dr. Reddy's Laboratories Limited Pharmaceuticals | DRREDDY | ₹1374.00 | +0.42% | ₹115K Cr | 35.5x | |
| 7 | Cipla Limited Pharmaceuticals | CIPLA | ₹1402.00 | +0.37% | ₹113K Cr | 33.6x | |
| 8 | Aurobindo Pharma Limited Pharmaceuticals | AUROPHARMA | ₹1705.00 | +0.62% | ₹98K Cr | 26.6x | |
| 9 | Lupin Limited Pharmaceuticals | LUPIN | ₹2008.60 | -0.36% | ₹92K Cr | 16.6x | |
| 10 | Alkem Laboratories Limited Pharmaceuticals | ALKEM | ₹5216.50 | -0.37% | ₹62K Cr | 28.9x |
Frequently Asked Questions
Why is Indian pharma considered defensive?
Because healthcare demand is often steadier than cyclical sectors. However, stock performance can be heavily influenced by US FDA regulatory actions, generic pricing pressure, and execution risk.
What should investors compare within pharma stocks?
Product mix, regulatory track record, domestic versus export exposure, US generics pipeline, ANDA filings, API integration depth, margin profile, and earnings durability.
What is the significance of USFDA approvals for Indian pharma companies?
USFDA approvals are critical for Indian pharma exporters as the US is their largest revenue market. Warning letters and import alerts can severely impact revenues, while new approvals drive growth rerating.
How do domestic-focused and export-focused pharma companies differ?
Domestic pharma companies benefit from branded generic pricing power and steady local demand. Export-heavy companies face US pricing pressure and regulatory risk but benefit from scale and currency tailwinds.